Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

HTLV-1 HBZ inhibits DHX9 to reprogram circRNA biogenesis in ATLL.

Created on 15 Jul 2026

Authors

Julien Ladet, Mateo Bazire, Nicolas Fontrodona, Anne Van den Broeke, Ambroise Marçais, Mariam Shallak, Greta Forlani, Roberto S Accolla, Cyril F Bourgeois, Franck Mortreux

Published in

Tumour virus research. Pages 200347. Jul 14, 2026. Epub Jul 14, 2026.

Abstract

Human T-cell Leukemia Virus type 1 (HTLV-1) drives Adult T-cell Leukemia/Lymphoma (ATLL) through sustained expression of the viral oncoprotein HBZ. Although HBZ is known to reshape host transcriptional programs, its role in post-transcriptional regulation in ATLL remains poorly understood. Here, we uncover a mechanism by which HBZ reprograms circular RNA (circRNA) biogenesis to support leukemic cell survival. Comprehensive circRNA profiling across ATLL subtypes revealed extensive circRNA remodeling, with distinct signatures associated with aggressive ATLL subtypes. Among these, circAFF2(3) is markedly upregulated in aggressive ATLL, and functional analyses show that its expression enhances, whereas its silencing reduces, the survival of HTLV-1-transformed T cells. Mechanistically, we show that HBZ interacts with the RNA helicase DHX9 and inhibits its helicase activity at intronic double-stranded RNA structures flanking circularized exons. Using both endogenous and synthetic circRNAs, we demonstrate that this inhibition allows RNA duplexes to persist, thereby promoting back-splicing and the accumulation of DHX9-sensitive circRNAs, including circAFF2(3). Together, these findings reveal that HTLV-1 hijacks host RNA helicase activity to reprogram circRNA biogenesis, identifying the HBZ-DHX9 axis as a novel post-transcriptional mechanism contributing to ATLL development.

PMID:
42448285
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement